Paloma Partners
RCKT icon

Paloma Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Paloma Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,675
Closed -$119K – 2367
2017
Q2 		$119K Buy
+15,675
New +$117K ﹤0.01% 2065
2017
Q1 		– Sell
-3,133
Closed -$76K – 2193
2016
Q4 		$76K Buy
+3,133
New +$89.4K ﹤0.01% 1917

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Pura Vida Investments
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GSA Capital Partners
GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paloma Partners's RCKT Position: Q3 2017 in Review

Paloma Partners sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 15,675 shares — an estimated $119K sold.

Paloma Partners first reported a position in RCKT in Q4 2016 and held it in 2 quarters. The position peaked at $119K in Q2 2017. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • Paloma Partners reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 15,675 Rocket Pharmaceuticals shares in Q3 2017, an estimated $119K.
  • Paloma Partners first reported a position in Rocket Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Paloma Partners's Rocket Pharmaceuticals position peaked at $119K in Q2 2017.
  • 35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.